UPDATE: Brookline Capital Markets Starts Caribou Biosciences Inc. (CRBU) at Buy

Brookline Capital Markets analyst Leah Rush Cann initiates coverage on Caribou Biosciences Inc. (NASDAQ: CRBU) with a Buy rating and a price target of $19.00.

The analyst comments "We currently estimate Caribou could launch CB-010 in B cell lymphomas in 2028; CB-011 in multiple myeloma in 2029; and CB-012 in acute myeloid leukemia in 2030. We estimate that the clinical stage products could account for $14.6 billion in product sales in 2030. These products include Caribou Biosciences’ phase I stage CB-010; and pre-clinical stage programs, CB-011 and CB-012. We estimate Caribou’s operating losses will continue until the launch of CB-010 in 2028. We project diluted EPS losses will
continue through 2028."

For an analyst ratings summary and ratings history on Caribou Biosciences Inc. click here. For more ratings news on Caribou Biosciences Inc. click here.

Shares of Caribou Biosciences Inc. closed at $10.71 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Caribou Biosciences Inc. (CRBU) PT Lowered to $5 at BofA Securities
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker